Morgan Stanley Maintains Overweight on National Instruments, Raises Price Target to $49

Morgan Stanley analyst Meta Marshall maintains National Instruments (NASDAQ:NATI) with a Overweight and raises the price target from $46 to $49.

byBenzinga Newsdesk

October 11, 2022

1 minute read

Morgan Stanley analyst Meta Marshall maintains National Instruments (NASDAQ:NATI) with a Overweight and raises the price target from $46 to $49.

Tigress Financial Downgrades Albertsons Companies to Neutral

By Benzinga Newsdesk

Today, 2:44 AM

Tigress Financial analyst Ivan Feinseth downgrades Albertsons Companies (NYSE:ACI) from Buy to Neutral.

ACI

C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers

By Ragothaman Srinivasan

Today, 2:44 AM

C4 Therapeutics, Inc. (C4T) (NASDAQ: CCCC) has dosed the first patient in the Phase 1/2 clinical trial of its drug candidate CFT8634, for the treatment of SMARCB1-perturbed cancers, including synovial sarcoma and SMARCB1-null tumors.

CCCC

Wellbeing Digital Reports 4Q Finances, ‘Three Key Pillars’ Stay Strong

By Lara Goldstein

Today, 2:44 AM

Wellbeing Digital Sciences Inc. (OTC: KONEF) filed its financial results for the quarter ended July 31, 2022 and provided some insight on their most recent businesses. Numbers for the selected period showed:

KONEF

Credit Suisse Maintains Outperform on Travel+Leisure, Lowers Price Target to $78

By Benzinga Newsdesk

Today, 2:44 AM

Credit Suisse analyst Benjamin Chaiken maintains Travel+Leisure (NYSE:TNL) with a Outperform and lowers the price target from $81 to $78.

TNL

Morgan Stanley Maintains Overweight on National Instruments, Raises Price Target to $49

Related Posts

Tigress Financial Downgrades Albertsons Companies to Neutral

C4 Therapeutics Doses First Patient in Phase 1/2 Trial of CFT8634 For SMARCB1-perturbed cancers

Wellbeing Digital Reports 4Q Finances, ‘Three Key Pillars’ Stay Strong

Credit Suisse Maintains Outperform on Travel+Leisure, Lowers Price Target to $78